SCHEMBL4458046

SCHEMBL4458046

Cc1ccc(NC(=O)c2ccc(-n3ccnc3C)c(C(F)(F)F)c2)cc1C(N)=O

nearest known ligand 0.49

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
BRAF P15056 2/20 0.49
KIT P10721 5/20 0.45
CSF1R P07333 3/20 0.45
BTK Q06187 3/20 0.45
LYN P07948 1/20 0.45
MAPK14 Q16539 4/20 0.44
KDR P35968 3/20 0.44
LCK P06239 3/20 0.44
TEK Q02763 2/20 0.44
TRPV1 Q8NER1 1/20 0.43
KDM4E B2RXH2 1/20 0.42
POLB P06746 1/20 0.42
ABL1 P00519 1/20 0.41
SRC P12931 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4458048 0.89 CSF1R (0.46) BRAFKITCSF1RBTKLYN
SCHEMBL2467864 0.87 KIT (0.46) BRAFKITCSF1RLYNMAPK14
SCHEMBL3302139 0.78 KCNQ3 (0.55) BRAFKITCSF1RBTKMAPK14
SCHEMBL13269565 0.78 LCK (0.52) KITCSF1RLYNKDRLCK
SCHEMBL4251497 0.78 BRAF (0.68) BRAFBTKKDR
SCHEMBL3300395 0.76 MAPT (0.55) BRAFKDM4E
SCHEMBL3528958 0.76 KDM4E (0.51) CSF1RKDM4E
SCHEMBL3143280 0.76 TNK2 (0.70) KITKDRLCKTEKABL1
SCHEMBL3388908 0.75 BRAF (0.53) BRAFKITCSF1RLYNMAPK14
SCHEMBL3530875 0.74 ABL1 (0.75) BRAFKITLYNMAPK14KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7589101-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2009-09-15 US claimed
US-20080287432-A1 Compounds and Compositions as Protein Kinase Inhibitors IRM LLC (BM) 2008-11-20 US claimed
EP-1919924-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM, LLC (BM) 2008-05-14 EP claimed
WO-2007022268-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2007-02-22 WO claimed
US-7589101-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2009-09-15 US disclosed
US-20080287432-A1 Compounds and Compositions as Protein Kinase Inhibitors IRM LLC (BM) 2008-11-20 US disclosed
EP-1919924-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM, LLC (BM) 2008-05-14 EP disclosed
WO-2007022268-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2007-02-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287432-A1 Compounds and Compositions as Protein Kinase Inhibitors AURKC, PTK2B, FRK BRAF 102/4885KIT 115/4885CSF1R 646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.